Anavex Life Sciences Corp. (NASDAQ:AVXL) announced its earnings results on Monday. The biotechnology company reported ($0.09) earnings per share for the quarter, meeting the consensus estimate of ($0.09), Bloomberg Earnings reports.

Shares of Anavex Life Sciences Corp. (NASDAQ:AVXL) traded down 2.28% on Tuesday, reaching $3.85. 110,952 shares of the company traded hands. Anavex Life Sciences Corp. has a 52-week low of $2.43 and a 52-week high of $6.64. The firm has a 50-day moving average of $5.12 and a 200-day moving average of $5.47. The company’s market capitalization is $159.30 million.

Several brokerages recently weighed in on AVXL. Maxim Group set a $15.00 target price on shares of Anavex Life Sciences Corp. and gave the company a “buy” rating in a research note on Monday. ValuEngine raised shares of Anavex Life Sciences Corp. from a “sell” rating to a “hold” rating in a research note on Thursday, August 3rd. Zacks Investment Research downgraded shares of Anavex Life Sciences Corp. from a “buy” rating to a “hold” rating in a research note on Wednesday, July 12th. Finally, Noble Financial reissued a “buy” rating on shares of Anavex Life Sciences Corp. in a research note on Sunday, May 14th. Two investment analysts have rated the stock with a hold rating and three have assigned a buy rating to the stock. The stock has a consensus rating of “Buy” and an average target price of $11.94.

COPYRIGHT VIOLATION NOTICE: This piece was first published by American Banking News and is owned by of American Banking News. If you are accessing this piece on another website, it was stolen and reposted in violation of international copyright & trademark legislation. The correct version of this piece can be read at https://www.americanbankingnews.com/2017/08/08/anavex-life-sciences-corp-avxl-issues-quarterly-earnings-results-meets-estimates.html.

About Anavex Life Sciences Corp.

Anavex Life Sciences Corp., is a clinical-stage biopharmaceutical company engaged in the development of drug candidates. The Company’s lead compounds include ANAVEX 2-73, ANAVEX PLUS, a combination of ANAVEX 2-73 with donepezil (Aricept), ANAVEX 19-144, ANAVEX 1-41, ANAVEX 7-1037, ANAVEX 3-71, ANAVEX 1079, ANAVEX 1519 and ANAVEX 1066 being developed to treat Alzheimer’s disease and other central nervous system (CNS) diseases.

Earnings History for Anavex Life Sciences Corp. (NASDAQ:AVXL)

Receive News & Ratings for Anavex Life Sciences Corp. Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Anavex Life Sciences Corp. and related companies with MarketBeat.com's FREE daily email newsletter.